Cargando…
Overexpression of BMI-1 Promotes Cell Growth and Resistance to Cisplatin Treatment in Osteosarcoma
BACKGROUND: BMI-1 is a member of the polycomb group of genes (PcGs), and it has been implicated in the development and progression of several malignancies, but its role in osteosarcoma remains to be elucidated. METHODOLOGY/PRINCIPAL FINDINGS: In the present study, we found that BMI-1 was overexpress...
Autores principales: | Wu, Zhihong, Min, Li, Chen, Dafu, Hao, Dongsheng, Duan, Yuanhui, Qiu, Guixing, Wang, Yipeng |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032734/ https://www.ncbi.nlm.nih.gov/pubmed/21311599 http://dx.doi.org/10.1371/journal.pone.0014648 |
Ejemplares similares
-
Volume-sensitive chloride channels are involved in cisplatin treatment of osteosarcoma
por: CAI, SIYI, et al.
Publicado: (2015) -
ITGB3 promotes cisplatin resistance in osteosarcoma tumors
por: Li, Qian, et al.
Publicado: (2023) -
BMI1 Is Expressed in Canine Osteosarcoma and Contributes to Cell Growth and Chemotherapy Resistance
por: Shahi, Mehdi Hayat, et al.
Publicado: (2015) -
Effects of NOB1 on the pathogenesis of osteosarcoma and its expression on the chemosensitivity to cisplatin
por: Luo, Leiming, et al.
Publicado: (2018) -
Mitochondrial APE1 promotes cisplatin resistance by downregulating ROS in osteosarcoma
por: Liu, Yufeng, et al.
Publicado: (2020)